SI2600839T1 - Farmacevtska odmerna oblika, ki obsega 6'-fluoro-(N-metil- ali N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano- (3,4,b)indol)-4-amin - Google Patents

Farmacevtska odmerna oblika, ki obsega 6'-fluoro-(N-metil- ali N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano- (3,4,b)indol)-4-amin Download PDF

Info

Publication number
SI2600839T1
SI2600839T1 SI201131434T SI201131434T SI2600839T1 SI 2600839 T1 SI2600839 T1 SI 2600839T1 SI 201131434 T SI201131434 T SI 201131434T SI 201131434 T SI201131434 T SI 201131434T SI 2600839 T1 SI2600839 T1 SI 2600839T1
Authority
SI
Slovenia
Prior art keywords
active agent
pharmacologically active
pharmaceutical formulation
general formula
formulation according
Prior art date
Application number
SI201131434T
Other languages
English (en)
Inventor
Marc Schiller
Nadja Gruning
Ingo Friedrich
Chris Kirby
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43481034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2600839(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of SI2600839T1 publication Critical patent/SI2600839T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Claims (10)

  1. Farmacevtska odmema oblika, ki obsega 6’-fluoro-(N-metil- ali N,N-dimetil-)-4-fenil -4’ ,9’-dihidro-3 ’H-spiro[cikloheksan-1,1 ’-pirano-[3,4,b]indol]-4-amin Patentni zahtevki
    1. Farmacevtska odmema oblika za dajanje dvakrat dnevno, enkrat dnevno ali manj pogosto, ki vsebuje farmakološko aktivno sredstvo s splošno formulo (I)
    v kjer je R -Hali-CH3, ali njegovo fiziološko sprejemljivo sol, ki skladno s Ph. Eur. pod in vitro pogoji v 900 mL umetnega želodčnega soka pri pH 1,2 in 37 °C ± 0,5 °C po 30 minutah po metodi z napravo z veslastim mešalom s svinčnico ("sinker") pri 100 vrt/min sprosti vsaj 50 mas. % farmakološko aktivnega sredstva, na osnovi celokupne količine farmakološko aktivnega sredstva, ki je prvotno vsebovana v farmacevtski odmemi obliki; in ki obsega trden polimerni matriksni material, v katerem je farmakološko aktivno sredstvo s splošno formulo (I) dispergirano in imobilizirano v amorfnem ali pol-amorfhem stanju, in kjer je polimer izbran iz skupine, ki jo sestavljajo polivinilpirolidon, vinilpirolidon-polivinilacetatni kopolimeri in njihove kakršne koli kombinacije; in kjer je relativno masno razmerje polimera glede na farmakološko aktivno sredstvo s splošno formulo (I) vsaj 6:1.
  2. 2. Farmacevtska odmema oblika po zahtevku 1, ki nadalje obsega surfaktant.
  3. 3. Farmacevtska odmema oblika po zahtevku 2, kjer - ima surfaktant HLB vrednost vsaj 10; in/ali - je vsebnost surfaktanta vsaj 0,001 mas. %, na osnovi celokupne mase farmacevtske odmeme oblike.
  4. 4. Farmacevtska odmema oblika po zahtevku 2 ali 3, kjer je surfaktant izbran iz skupine, ki jo sestavljajo polioksietilen maščobnokislinski estri, delni maščobnokislinski estri polioksietilensorbitana in estri žveplove kisline.
  5. 5. Farmacevtska odmema oblika po katerem koli od predhodnih zahtevkov, kjer ima farmakološko aktivno sredstvo s splošno formulo (I) stereokemijo s splošno formulo (Γ)
    kjer je R definiran kot v zahtevku 1.
  6. 6. Farmacevtska odmema oblika po katerem koli od predhodnih zahtevkov, kjer je farmakološko aktivno sredstvo s splošno formulo (I) (1 r,4r)-6 ’-fluoro-N,N-dimetil-4-fenil-4 ’ ,9 ’-dihidro-3’H-spiro[cikcloheksan-1,1 ’-pirano[3,4,b]indol]-4-amin, (1 r,4r)-6 ’ -fhioro-N-metil-4-fenil-4 ’ ,9 ’ -dihidro-3 ’H-spiro[cikloheksan-1, Γ -pirano-[3,4,b]indol]-4-amin ali fiziološko sprejemljiva sol le-teh.
  7. 7. Farmacevtska odmema oblika po katerem koli od predhodnih zahtevkov, ki pod in vitro pogoji v 900 mL umetnega želodčnega soka pri pH 1,2 po 30 minutah sprosti vsaj 80 mas. % farmakološko aktivnega sredstva s splošno formulo (I), na osnovi celokupne količine farmakološko aktivnega sredstva s formulo (I), ki je prvotno vsebovana v odmemi obliki.
  8. 8. Farmacevtska odmema oblika po katerem koli od predhodnih zahtevkov, ki vsebuje farmakološko aktivno sredstvo s splošno formulo (I) v odmerku od 10 pg do 50 pg ali od 300 pg do 500 pg.
  9. 9. Farmacevtska odmema oblika po katerem koli od predhodnih zahtevkov za uporabo v zdravljenju bolečine.
  10. 10. Farmacevtska odmema oblika po zahtevku 9, kjer je bolečina izbrana izmed akutne, visceralne, nevropatske ali kronične bolečine.
SI201131434T 2010-08-04 2011-08-04 Farmacevtska odmerna oblika, ki obsega 6'-fluoro-(N-metil- ali N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano- (3,4,b)indol)-4-amin SI2600839T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37064310P 2010-08-04 2010-08-04
EP10008116 2010-08-04
EP11746175.6A EP2600839B1 (en) 2010-08-04 2011-08-04 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
PCT/EP2011/003909 WO2012016699A2 (en) 2010-08-04 2011-08-04 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Publications (1)

Publication Number Publication Date
SI2600839T1 true SI2600839T1 (sl) 2018-04-30

Family

ID=43481034

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131434T SI2600839T1 (sl) 2010-08-04 2011-08-04 Farmacevtska odmerna oblika, ki obsega 6'-fluoro-(N-metil- ali N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano- (3,4,b)indol)-4-amin

Country Status (28)

Country Link
EP (1) EP2600839B1 (sl)
JP (1) JP5792300B2 (sl)
KR (1) KR101828768B1 (sl)
CN (1) CN103179953A (sl)
AR (1) AR082560A1 (sl)
AU (1) AU2011287956B2 (sl)
BR (1) BR112013002714A2 (sl)
CA (1) CA2804878C (sl)
CL (1) CL2012003582A1 (sl)
CO (1) CO6640315A2 (sl)
CY (1) CY1119887T1 (sl)
DK (1) DK2600839T3 (sl)
EC (1) ECSP13012419A (sl)
ES (1) ES2665344T3 (sl)
HR (1) HRP20180143T1 (sl)
HU (1) HUE035543T2 (sl)
IL (1) IL223880A (sl)
LT (1) LT2600839T (sl)
MX (1) MX345068B (sl)
NZ (1) NZ604735A (sl)
PE (1) PE20131107A1 (sl)
PL (1) PL2600839T3 (sl)
PT (1) PT2600839T (sl)
RS (1) RS57027B1 (sl)
RU (1) RU2582390C2 (sl)
SI (1) SI2600839T1 (sl)
WO (1) WO2012016699A2 (sl)
ZA (1) ZA201300038B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642853A (zh) 2015-01-23 2016-12-16 歌林達有限公司 用於治療肝功能之損傷及／或腎功能之損傷個體疼痛之西博帕多（Ｃｅｂｒａｎｏｐａｄｏｌ）
BR112018017167A2 (pt) 2016-02-29 2019-01-02 Gruenenthal Gmbh titulação de cebranopadol
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
WO2024173714A1 (en) 2023-02-15 2024-08-22 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate

Also Published As

Publication number Publication date
HUE035543T2 (en) 2018-05-28
CY1119887T1 (el) 2018-06-27
ES2665344T3 (es) 2018-04-25
NZ604735A (en) 2014-08-29
IL223880A (en) 2017-01-31
KR101828768B1 (ko) 2018-02-13
ZA201300038B (en) 2013-09-25
EP2600839B1 (en) 2018-01-10
CN103179953A (zh) 2013-06-26
CL2012003582A1 (es) 2013-06-07
WO2012016699A2 (en) 2012-02-09
HRP20180143T1 (hr) 2018-02-23
JP5792300B2 (ja) 2015-10-07
AU2011287956A8 (en) 2014-09-25
PL2600839T3 (pl) 2018-07-31
MX345068B (es) 2017-01-16
PE20131107A1 (es) 2013-10-17
PT2600839T (pt) 2018-04-17
AU2011287956A1 (en) 2013-01-10
RU2582390C2 (ru) 2016-04-27
KR20130135238A (ko) 2013-12-10
RU2013109134A (ru) 2014-09-10
CA2804878C (en) 2019-01-08
MX2013001114A (es) 2013-03-12
WO2012016699A8 (en) 2013-02-07
WO2012016699A3 (en) 2012-08-16
ECSP13012419A (es) 2013-03-28
EP2600839A2 (en) 2013-06-12
CA2804878A1 (en) 2012-02-09
AR082560A1 (es) 2012-12-19
JP2013532698A (ja) 2013-08-19
RS57027B1 (sr) 2018-05-31
DK2600839T3 (da) 2018-01-29
LT2600839T (lt) 2018-03-26
AU2011287956B2 (en) 2015-01-22
BR112013002714A2 (pt) 2017-05-30
CO6640315A2 (es) 2013-03-22

Similar Documents

Publication Publication Date Title
HRP20151337T1 (hr) Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil- ili n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin
HRP20180904T1 (hr) Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za liječenje neuropatske boli
HRP20180143T1 (hr) Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil- ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin
RU2013109136A (ru) ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ-ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН
WO2013032744A3 (en) Compositions and methods for increasing desirable microbiota
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
NZ610701A (en) Once daily formulation of lacosamide
WO2010081824A3 (en) Active coating of pharmaceutical dosage forms
JP2013533230A5 (sl)
WO2008107149A3 (de) Darreichungsform mit erschwertem missbrauch
NZ589017A (en) Solid pharmaceutical formulation with delayed release
WO2008071407A3 (de) Beschichtete pellets
WO2011042463A3 (en) Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
FI3324948T3 (fi) Monikerroksisia farmaseuttisesti aktiivista yhdistettä vapauttavia mikropartikkeleita nestemäisessä annosmuodossa
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
WO2010113177A3 (en) Oral insulin delivery systems for controlling diabetes
EA200971132A1 (ru) Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц
Chuenbarn et al. Doxycycline hyclate-loaded Eudragit® RS PO in situ-forming microparticles for periodontitis treatment
EP3391874A3 (en) Delivery devices containing encapsulated and/or particle- bound active pharmaceutical ingredients
CA2939604A1 (en) Compositions and methods of treatment comprising fosfomycin disodium
RU2015119243A (ru) Твердые дисперсии нерастворимого лекарственного средства и способы их приготовления
Mishra An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis
CN109496152B (zh) 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法
RU2007113156A (ru) Твердая нанокомпозиция для доставки биологически активных веществ